Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Olimpieri O, Pane F, Iurlo A, Foggi P, Cirilli A, Colatrella A, Cuomo M, Gozzo L, Summa V, Corradini P, Russo P; AIFA’s Monitoring Registries Group. Breccia M, et al. Among authors: gozzo l. Cancer Med. 2020 Jun;9(12):4160-4165. doi: 10.1002/cam4.3071. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319737 Free PMC article.
Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries.
Olimpieri PP, Di Lenarda A, Mammarella F, Gozzo L, Cirilli A, Cuomo M, Gulizia MM, Colivicchi F, Murri G, Gabrielli D, Trotta F. Olimpieri PP, et al. Among authors: gozzo l. Int J Cardiol Heart Vasc. 2020 Jan 23;26:100465. doi: 10.1016/j.ijcha.2019.100465. eCollection 2020 Feb. Int J Cardiol Heart Vasc. 2020. PMID: 32021902 Free PMC article.
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M, Celant S, Olimpieri PP, Olimpieri OM, Pane F, Iurlo A, Cirilli A, Colatrella A, Gozzo L, Pugliese S, Summa V, Foggi P, Corradini P, Russo P; AIFA Monitoring Registries Group. Breccia M, et al. Among authors: gozzo l. Ann Hematol. 2021 Feb;100(2):481-485. doi: 10.1007/s00277-021-04406-1. Epub 2021 Jan 7. Ann Hematol. 2021. PMID: 33415425
The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice.
Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W, Torrisi SA, Giurdanella G, Piazza C, Impellizzeri AR, Gozzo L, Navarria A, Bucolo C, Nicoletti F, Palmeri A, Salomone S, Copani A, Caraci F, Drago F. Leggio GM, et al. Among authors: gozzo l. Pharmacol Res. 2016 Apr;106:10-20. doi: 10.1016/j.phrs.2016.02.007. Epub 2016 Feb 10. Pharmacol Res. 2016. PMID: 26875816
Response to Letter to the Editor by Dr. Garattini.
Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Drago F. Navarria A, et al. Among authors: gozzo l. Value Health. 2016 Jun;19(4):510. doi: 10.1016/j.jval.2015.01.007. Epub 2015 Apr 15. Value Health. 2016. PMID: 27325344 Free article. No abstract available.
43 results